FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028681024> ?p ?o ?g. }

• W2028681024 endingPage "1035" @default.
• W2028681024 startingPage "1022" @default.
• W2028681024 abstract "Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K-AKT activation, prolonged early G1 arrest induced by PD 0332991 (palbociclib) inhibition of CDK4 sensitized resistant lymphoma cells to ibrutinib killing when BTK was unmutated, and to PI3K inhibitors independent of C481S mutation. These data identify a genomic basis for acquired ibrutinib resistance in MCL and suggest a strategy to override both primary and acquired ibrutinib resistance.We have discovered the first relapse-specific BTK mutation in patients with MCL with acquired resistance, but not primary resistance, to ibrutinib, and demonstrated a rationale for targeting the proliferative resistant MCL cells by inhibiting CDK4 and the cell cycle in combination with ibrutinib in the presence of BTK(WT) or a PI3K inhibitor independent of BTK mutation. As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. Cancer Discov; 4(9); 1022-35. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 973." @default.
• W2028681024 created "2016-06-24" @default.
• W2028681024 creator A5000554189 @default.
• W2028681024 creator A5010173185 @default.
• W2028681024 creator A5013007045 @default.
• W2028681024 creator A5021564306 @default.
• W2028681024 creator A5028436152 @default.
• W2028681024 creator A5035164689 @default.
• W2028681024 creator A5037882455 @default.
• W2028681024 creator A5040141808 @default.
• W2028681024 creator A5043717032 @default.
• W2028681024 creator A5049405375 @default.
• W2028681024 creator A5061702711 @default.
• W2028681024 creator A5062625211 @default.
• W2028681024 creator A5080066418 @default.
• W2028681024 creator A5080145536 @default.
• W2028681024 creator A5083277645 @default.
• W2028681024 creator A5085435765 @default.
• W2028681024 creator A5088809839 @default.
• W2028681024 date "2014-09-01" @default.
• W2028681024 modified "2023-10-16" @default.
• W2028681024 title "Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma" @default.
• W2028681024 cites W1974788142 @default.
• W2028681024 cites W1977342543 @default.
• W2028681024 cites W1991276398 @default.
• W2028681024 cites W1997671124 @default.
• W2028681024 cites W2007886976 @default.
• W2028681024 cites W2008065206 @default.
• W2028681024 cites W2010753128 @default.
• W2028681024 cites W2013909810 @default.
• W2028681024 cites W2016663561 @default.
• W2028681024 cites W2024040061 @default.
• W2028681024 cites W2025786205 @default.
• W2028681024 cites W2027971058 @default.
• W2028681024 cites W2029754521 @default.
• W2028681024 cites W2031530131 @default.
• W2028681024 cites W2035277099 @default.
• W2028681024 cites W2038053631 @default.
• W2028681024 cites W2041694372 @default.
• W2028681024 cites W2042652801 @default.
• W2028681024 cites W2043275534 @default.
• W2028681024 cites W2044348066 @default.
• W2028681024 cites W2045827067 @default.
• W2028681024 cites W2059410730 @default.
• W2028681024 cites W2067064694 @default.
• W2028681024 cites W2067257663 @default.
• W2028681024 cites W2071549499 @default.
• W2028681024 cites W2073359527 @default.
• W2028681024 cites W2089928288 @default.
• W2028681024 cites W2104167441 @default.
• W2028681024 cites W2125211913 @default.
• W2028681024 cites W2141869983 @default.
• W2028681024 cites W2148931486 @default.
• W2028681024 cites W2154066874 @default.
• W2028681024 cites W2160367702 @default.
• W2028681024 cites W2163690533 @default.
• W2028681024 cites W2169450835 @default.
• W2028681024 cites W4205407880 @default.
• W2028681024 cites W4232893725 @default.
• W2028681024 cites W4240663725 @default.
• W2028681024 doi "https://doi.org/10.1158/2159-8290.cd-14-0098" @default.
• W2028681024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4155003" @default.
• W2028681024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25082755" @default.
• W2028681024 hasPublicationYear "2014" @default.
• W2028681024 type Work @default.
• W2028681024 sameAs 2028681024 @default.
• W2028681024 citedByCount "230" @default.
• W2028681024 countsByYear W20286810242015 @default.
• W2028681024 countsByYear W20286810242016 @default.
• W2028681024 countsByYear W20286810242017 @default.
• W2028681024 countsByYear W20286810242018 @default.
• W2028681024 countsByYear W20286810242019 @default.
• W2028681024 countsByYear W20286810242020 @default.
• W2028681024 countsByYear W20286810242021 @default.
• W2028681024 countsByYear W20286810242022 @default.
• W2028681024 countsByYear W20286810242023 @default.
• W2028681024 crossrefType "journal-article" @default.
• W2028681024 hasAuthorship W2028681024A5000554189 @default.
• W2028681024 hasAuthorship W2028681024A5010173185 @default.
• W2028681024 hasAuthorship W2028681024A5013007045 @default.
• W2028681024 hasAuthorship W2028681024A5021564306 @default.
• W2028681024 hasAuthorship W2028681024A5028436152 @default.
• W2028681024 hasAuthorship W2028681024A5035164689 @default.
• W2028681024 hasAuthorship W2028681024A5037882455 @default.
• W2028681024 hasAuthorship W2028681024A5040141808 @default.
• W2028681024 hasAuthorship W2028681024A5043717032 @default.
• W2028681024 hasAuthorship W2028681024A5049405375 @default.
• W2028681024 hasAuthorship W2028681024A5061702711 @default.
• W2028681024 hasAuthorship W2028681024A5062625211 @default.
• W2028681024 hasAuthorship W2028681024A5080066418 @default.
• W2028681024 hasAuthorship W2028681024A5080145536 @default.
• W2028681024 hasAuthorship W2028681024A5083277645 @default.
• W2028681024 hasAuthorship W2028681024A5085435765 @default.
• W2028681024 hasAuthorship W2028681024A5088809839 @default.
• W2028681024 hasBestOaLocation W20286810241 @default.
• W2028681024 hasConcept C203014093 @default.
• W2028681024 hasConcept C2777525834 @default.
• W2028681024 hasConcept C2777938653 @default.

• next